Fig. 5
Antigen-specific CD8+ T cells are critical for gCpG treatment. a Tumor foci of vaccine-treated mice were injected i.p. with 1 mg GK1.5 (anti-mouse CD4 mAb) or 53–6.7 (anti-mouse CD8 mAb) 2 days before the first immunization, and the injections were repeated 7 days later. Mice were sacrificed on day 7 post the last immunization and the metastatic nodules were counted. b 8 × 105 B16-OVA were i.v. injected into each mouse from tail vein. On day 7, 3 × 106 CD8+ T cells isolated from spleen of tumor-bearing mice treated with PBS or gCpG + OVA were i.v. injected into tumor-bearing mice. Mice were sacrificed and the metastatic nodules in lung were counted 12 days later. c Mice with B16-F10 metastasis were adoptively transferred with 3 × 106 T cells from gCpG + OVA treated mice. Mice were sacrificed and the metastatic nodules in lung were counted 12 days later. *p < 0.05 and **p < 0.01, ***p < 0.001 and ****p < 0.0001